Oxidative stress and Down syndrome. do antioxidants play a role in therapy?

Physiological Research

Volumn 63, Issue 5, 2014, Pages 535-542

  Muchova J ^a   Zitnanova I ^a   Durackova Z ^a  

^a Physics and Informatics   (Slovakia)

Author keywords

Cognitive functions; Down syndrome; Oxidative stress; Physical activities; Polyphenols

Indexed keywords

ANTIOXIDANT;

BRAIN; COGNITION; DOWN SYNDROME; DRUG EFFECTS; EXERCISE; GENETIC PREDISPOSITION; GENETICS; HUMAN; LEARNING; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PSYCHOLOGY; TREATMENT OUTCOME;

ANTIOXIDANTS; BRAIN; COGNITION; DOWN SYNDROME; EXERCISE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEARNING; OXIDATIVE STRESS; PHENOTYPE; TREATMENT OUTCOME;

EID: 84920036981     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. ANDRIOLO RB, EL DIB RP, RAMOS L, ATALLAH ÁN, DA SILVA EMK: Aerobic exercise training programmes for improving physical and psychosocial health in adults with Down syndrome (Review). John Wiley & Sons, New York, 2011, pp 1-42. DOI: 10.1002/14651858.CD005176.pub4
2. ANNERÉN G, MAGNUSSON CG, NORDVALL SL: Increase in serum concentrations of IgG2 and IgG4 by selenium supplementation in children with Down's syndrome. Arch Dis Child 65: 1353-1355, 1990.
3. BERCHTOLD NC, CASTELLO N, COTMAN CW: Exercise and time-dependent benefits to learning and memory. Neuroscience 167: 588-597, 2010.
4. CASO G, KELLY P, MCNURLAN MA, LAWSON WE: Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 99: 1409-1412, 2007.
5. CHANG KT, MIN KT: Drosophila melanogaster homolog of Down syndrome critical region 1 is critical for mitochondrial function. Nat Neurosci 8: 1577-1585, 2005.
6. CHATURVEDI RK, BEAL MF: Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci 1147: 395-412, 2008.
7. CORRALES A, MARTÍNEZ P, GARCÍA S, VIDAL V, GARCÍA E, FLÓREZ J, SANCHEZ-BARCELÓ EJ, MARTÍNEZ-CUÉ C, RUEDA N: Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome. J Pineal Res 54: 346-358, 2013.
8. COTMAN CW, BERCHTOLD NC: Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 25: 295-301, 2002.
9. COTMAN CW, ENGESSER-CESAR C: Exercise enhances and protects brain function. Exerc Sport Sci Rev 30: 75-79, 2002.
10. COTMAN CW, HEAD E, MUGGENBURG BA, ZICKER S, MILGRAM NW: Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol Aging 23: 809-818, 2002.
11. DE LA TORRE R, DIERSSEN M: Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future. Prog Brain Res 197: 1-14, 2012.
12. ĎURAČKOVÁ Z: Oxidative stress. (in Slovak) In: Diagnosis Down Syndrome. ŠUSTROVÁ M, MIŠOVICOVÁ N, ČERNAY J, BÜCHLER P, ČERVEŇOVÁ O, ĎURAČKOVÁ Z, ALGAYEROVÁ M (eds), Perfekt, Bratislava, 2004, pp 208-212.
13. ĎURAČKOVÁ Z: Some current insights into oxidative stress. Physiol Res 59: 459-469, 2010.
14. ELLIS JM, TAN HK, GILBERT RE, MULLER DP, HENLEY W, MOY R, PUMPHREY R, ANI C, DAVIES S, EDWARDS V, GREEN H, SALT A, LOGAN S: Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial. BMJ 336: 594-597, 2008.
15. FERRIS LT, WILLIAMS JS, SHEN CL: The effect of acute exercise on serum brain-derived neurotrophic factor levels and cognitive function. Med Sci Sports Exerc 39: 728-734, 2007.
16. GARAIOVÁ I, MUCHOVÁ J, ŠUSTROVÁ M, BLAŽÍČEK P, SIVOŇOVÁ M, KVASNIČKA, P, PUESCHEL S, ĎURAČKOVÁ Z: The relationship between antioxidant systems and some markers of oxidative stress in persons with Down syndrome. Biologia 59: 787-794, 2004.
17. GOMEZ-PINILLA F, NGUYEN TTJ: Natural mood foods: the actions of polyphenols against psychiatric and cognitive disorders. Nutr Neurosci 15: 127-133, 2012.
18. KADRABOVÁ J, MADARIC A, SUSTROVÁ M, GINTER E: Changed serum trace element profile in Down's syndrome. Biol Trace Elem Res 54: 201-206, 1996.
19. KEDZIORA J, BARTOSZ G: Down's syndrome: a pathology involving the lack of balance of reactive oxygen species. Free Radic Biol Med 4: 317-330, 1988.
20. KLEIN AB, WILLIAMSON R, SANTINI MA, CLEMMENSEN C, ETTRUP A, RIOS M, KNUDSEN GM, AZNAR S: Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 14: 347-353, 2011.
21. LITTBRAND H, STENVALL M, ROSENDAHL E: Applicability and effects of physical exercise on physical and cognitive functions and activities of daily living among people with dementia: a systematic review. Am J Phys Med Rehabil 90: 495-518, 2011.
22. LOCKITCH G, PUTERMAN M, GODOLPHIN W, SHEPS S, TINGLE AJ, QUIGLEY G: Infection and immunity in Down syndrome: a trial of long-term low oral doses of zinc. J Pediatr 114: 781-787, 1989.
23. LOTT IT: Antioxidants in Down syndrome. Biochim Biophys Acta 1822: 657-663, 2012.
24. LOTT IT, HEAD E, DORAN E, BUSCIGLIO J: Beta-amyloid, oxidative stress and Down syndrome. Curr Alzheimer Res 3: 521-528, 2006.
25. LOTT IT, DORAN E, NGUYEN VQ, TOURNAY A, HEAD E, GILLEN DL: Down syndrome and dementia:a randomized, controlled trial of antioxidant supplementation. Am J Med Genet A 155A: 1939-1948, 2011.
26. MANCUSO M, ORSUCCI D, VOLPI L, CALSOLARO V, SICILIANO G: Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets 11: 111-121, 2010.
27. MEGUID NA, KHOLOUSSI NM, AFIFI HH: Evaluation of superoxide dismutase and glutathione peroxidase enzymes and their cofactors in Egyptian children with Down's syndrome. Biol Trace Elem Res 81: 21-28, 2001.
28. MILES MV: Evaluation of Coenzyme q10 (Liq-nol®) Efficacy in Pediatric Patients With Down Syndrome. ClinicalTrials.gov NCT00891917. http://www.clinicaltrials.gov/ct2/show/NCT00891917?term=Efficacy+in+pediatric+patients&rank=1
29. MONTI D, TROIANO L, TROPEA F, GRASSILLI E, COSSARIZZA A, BAROZZI D, PELLONI MC, TAMASSIA MG, BELLOMO G, FRANCESCHI C: Apoptosis-programmed cell death: a role in the aging process? Am J Clin Nutr 55: 1208S-1214S, 1992.
30. MORAWIEC Z, JANIK K, KOWALSKI M, STETKIEWICZ T, SZAFLIK J, MORAWIEC-BAJDA A, SOBCZUK A, BLASIAK J: DNA damage and repair in children with Down's syndrome. Mutat Res 637: 118-123, 2008.
31. MUCHOVÁ J, ŠUSTROVÁ M, GARAIOVÁ I, LIPTÁKOVÁ A, BLAŽÍČEK P, KVASNIČKA P, PUESCHEL S, ĎURAČKOVÁ Z: Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes and neutrophils of Down syndrome patients. Free Radic Biol Med 31: 499-508, 2001.
32. MUCHOVÁ J, GARAIOVÁ I, ŠUSTROVÁ M, LIPTÁKOVÁ A, BLAŽÍČEK P, KVASNIČKA P, ĎURAČKOVÁ Z: The redox state of glutathione in erythrocytes of individuals with Down syndrome. Bratisl Lek Listy 108: 70-74, 2007.
33. ONO K, HASEGAWA K, NAIKI H, YAMADA M: Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro. Biochem Biophys Res Commun 330: 111-116, 2005.
34. PAGANO G, CASTELLO G: Oxidative stress and mitochondrial dysfunction in Down syndrome. In:Neurodegenerative Diseases. SI AHMAD (ed), Landes Bioscience, Austin and Springer Science+Business Media, New York, 2012, pp 291-299.
35. PALACKA P, KUCHARSKA J, MURIN J, DOSTALOVA K, OKKELOVA A, CIZOVA M, WACZULIKOVA I, MORICOVA S, GVOZDJAKOVA A: Complementary therapy in diabetic patients with chronic complications: a pilot study. Bratisl Lek Listy 111: 205-211, 2010.
36. PALLARDÓ FV, LLORET A, LEBEL M, D'ISCHIA M, COGGER VC, LE COUTEUR DG, GADALETA MN, CASTELLO G, PAGANO G: Mitochondrial dysfunction in some oxidative stress-related genetic diseases:Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome. Biogerontology 11: 401-419, 2010.
37. PONS-ESPINAL M, MARTINEZ DE LAGRAN M, DIERSSEN M: Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A. Neurobiol Dis 60: 18-31, 2013.
38. RODRIGUEZ MC, MACDONALD JR, MAHONEY DJ, PARISE G, BEAL MF, TARNOPOLSKY MA: Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 35: 235-242, 2007.
39. SMITH B, MEDDA F, GOKHALE V, DUNCKLEY T, HULME C: Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?. ACS Chem Neurosci 3: 857-872, 2012.
40. STRYDOM A, DICKINSON MJ, SHENDE S, PRATICO D, WALKER Z: Oxidative stress and cognitive ability in adults with Down syndrome. Prog Neuropsychopharmacol Biol Psychiatry 33: 76-80, 2009.
41. SUBBA RAO K: Mechanisms of disease: DNA repair defects and neurological disease. Nat Clin Pract Neurol 3: 162-172, 2007.
42. ŠUSTROVÁ M: Down syndrome at the present time. (in Slovak). Pediatr Prax 4: 202-205, 2007.
43. ŠUSTROVÁ M, ŠARÍKOVÁ V: Down's syndrome-effect of increased gene expression in chromosome 21 on the function of the immune and nervous system. (in Slovak). Bratisl Lek Listy 98: 221-228, 1997.
44. ŠUSTROVÁ M, MIŠOVICOVÁ N, ČERNAY J, BÜCHLER P, ČERVEŇOVÁ O, ĎURAČKOVÁ Z, ALGAYEROVÁ M: Diagnosis Down Syndrome. (in Slovak) Perfekt, Bratislava, 2004, 240 p.
45. TAN YH, TISCHFIELD J, RUDDLE FH: The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21. J Exp Med 137: 317-330, 1973.
46. TARNOPOLSKY MA: The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv Drug Deliv Rev 60: 1561-1567, 2008.
47. TIANO L, BUSCIGLIO J: Mitochondrial dysfunction and Down's syndrome: is there a role for coenzyme Q(10)?. Biofactors 37: 386-392, 2011.
48. UBEROS J, ROMERO J, MOLINA-CARBALLO A, MUÑOZ-HOYOS A: Melatonin and elimination of kynurenines in children with Down's syndrome. J Pediatr Endocrinol Metab 23: 277-282, 2010.
49. WEISS V: Psychometric intelligence correlates with interindividual different rates of lipid peroxidation. Biomed Biochim Acta 43: 755-763, 1984.
50. ZAMBRANO JC, MARQUINA R, SULBARÁN N, RODRÍGUEZ-MALAVER AJ, REYES RA: Aerobic exercise reduced oxidative stress in saliva of persons with Down syndrome. Res Sports Med 17: 195-203, 2009.
51. ZANA M, SZÉCSÉNYI A, CZIBULA A, BJELIK A, JUHÁSZ A, RIMANÓCZY A, SZABÓ K, VETRÓ A, SZUCS P, VÁRKONYI A, PÁKÁSKI M, BODA K, RASKÓ I, JANKA Z, KÁLMÁN J: Age-dependent oxidative stress-induced DNA damage in Down's lymphocytes. Biochem Biophys Res Commun 345: 726-733, 2006.
52. ŽITŇANOVÁ I, KORYTÁR P, ARUOMA OI, ŠUSTROVÁ M, GARAIOVÁ I, MUCHOVÁ J, KALNOVIČOVÁ T, PUESCHEL S, ĎURAČKOVÁ Z: Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms?. Clin Chim Acta 341: 139-146, 2004.
53. ŽITŇANOVÁ I, KORYTÁR P, SOBOTOVÁ H, HORÁKOVÁ Ľ, ŠUSTROVÁ M, PUESCHEL S, ĎURAČKOVÁ Z: Markers of oxidative stress in children with Down syndrome. Clin Chem Lab Med 44: 306-310, 2006.